REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of four posters at the American Society of Gene & Cell Therapy (ASGCT) 2019 Annual Meeting in Washington, D.C., from April 29 to May 2, 2019.
|
ROCKVILLE, Md., April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of four posters at the American Society of Gene & Cell Therapy (ASGCT) 2019 Annual Meeting in Washington, D.C., from April 29 to May 2, 2019. The data will be presented as follows: Abstract Title: Determination of AAV Genome Content and Capsid Content by Size Exclusion Chromatography (abstract #184) Abstract Title: Assessing Purity and Structures of AAV Vector Genomes by High Performance Size Exclusion Chromatography (abstract #174) Abstract Title: Structure-Guided Engineering of Surface-Exposed Loops on the AAV Capsid (abstract #466) Abstract Title: Validation of AAV Transgene-Specific Quantification Assay Using BioRad Droplet Digital PCR (abstract #734) About REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas. Contacts: Investors: Media:
SOURCE REGENXBIO Inc. |
||
Company Codes: NASDAQ-NMS:RGNX |
View original content to download multimedia:
